7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate,
fluindostatin,
fluvastatin,
fluvastatin sodium,
fluvastatin sodium salt,
Lescol,
XU 62 320,
XU 62-320,
XU 62320,
XU-62320,
XU62320,
FLUVASTATIN SODIUM,
Lescol,
93957-55-2,
Fluvastatin sodium salt,
Vastin,
Canef,
Sri-62320,
Fluvastatin sodium (Lescol),
Fractal,
Lipaxan,
Locol,
XU-62-320,
CHEBI:77602,
Lescol XL,
XU 62-320,
C24H25FNNaO4,
DSSTox_CID_24758,
DSSTox_RID_80451,
DSSTox_GSID_44758,
(3R,5S)-Fluvastatin Sodium Salt,
SMR000550480,
94061-80-0,
Lochol,
AB01274723-01,
Sri 62320,
Xilep XL,
Fluindostatin sodium,
Sodium (3R,5S,E)-7-(3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoate,
CAS-93957-55-2,
Prestwick_1032,
Fluvastatin (sodium),
Fluyastatin Sodium Salt,
(+)-fluvastatin sodium,
Fluvastatin Sodium,(S),
NCGC00164604-01,
Fluvastatin-d6 sodium salt,
Fluvastatin-Sodium(Lescol),
(3r,5s)-fluvastatin sodium,
SCHEMBL41502,
MLS001165673,
MLS001304715,
MLS006010060,
CHEMBL333442,
DTXSID3044758,
ZGGHKIMDNBDHJB-NRFPMOEYSA-M,
HMS1570L19,
HMS2233N10,
XU 62-320;Canef;Vastin;Lescol,
(+)-(3R,5S)-fluvastatin sodium,
(3R,5S)-(+)-fluvastatin sodium,
(3S,5R)-7-(3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid sodium salt,
sodium;(E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoate,
Tox21_112226,
s1909,
XU-620,
(+)-3R,5S-Fluvastatin sodium salt,
AKOS016340657,
Tox21_112226_1,
AC-6856,
AN-6324,
API0002750,
API0005677,
KS-1062,
NCGC00263525-01,
AB2000367,
ST24047218,
SW197104-2,
J90003,
UNII-PYF7O1FV7F component ZGGHKIMDNBDHJB-NRFPMOEYSA-M,
(3R,5S)-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic Acid Sodium Salt,
(3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy hept-6-enoic acid sodium salt,
(3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid sodium salt,
(3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic Acid Sodium Salt,
(e)-(3r,5s)-(+)-7-[3-(4-fluoro-phenyl)-1-isopropyl-1h-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid sodium salt,
(e)-(3r,5s)-7-[3-(4-fluoro-phenyl)-1-isopropyl-1h-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid sodium salt,
(e)-(3r,5s)-7-[3-(4-fluoro-phenyl)-1-isopropyl-1h-indol-2-yl]-3,5-dihydroxy-hept-6enoic acid sodium salt,
155229-75-7,
6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-, monosodium salt, (S-(R*,S*-(E)))-,
sodium (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoate,
sodium (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropylindol-2-yl]-3,5-dihydroxyhept-6-enoate,
Sodium (E)-(3R,5S)-7-[3-(4-fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoate,
sodium (E,3R,5S)-7-[3-(4-fluorophenyl)-1-isopropyl-indol-2-yl]-3,5-dihydroxy-hept-6-enoate,
fluvastatin,
Fluindostatin,
Primesin,
Primexin,
Lymetel,
Cranoc,
Fluvastatin Sanabo,
UNII-PYF7O1FV7F,
Fluvastatin sodium [USAN],
C24H26FNO4.Na,
CCRIS 6848,
Fluvastatin sodium [USAN:USP],
C24-H26-F-N-O4.Na,
ACN-048183,
CID6420065,
93957-54-1,
Sodium (+-)-(3R*,5S*,6E)-7-(3-(p-fluorophenyl)-1-isopropylindol-2-yl)-3,5-dihydroxy-6-heptenoate,